New York, USA – Oct 11, 2018 – Vortex Biosciences’ VTX-1 circulating tumour cell (CTC) platform, commercialized late last year, is rapidly gaining traction among investigators for its ability to unlock new applications in liquid biopsy research. Recent reports highlight the system’s versatility, showcasing its utility beyond traditional biomarker analysis.
Researchers are leveraging the VTX-1 to investigate existing biomarkers such as EGFR and PD-L1, providing deeper insights into cancer progression and treatment response. Crucially, the platform’s unique capability to separate and partition viable CTCs is enabling novel studies into the functioning of these cells—an avenue previously inaccessible. This advancement holds immense promise for developing more effective diagnostic tools and personalized therapeutic strategies in oncology.
